[JS] ASGCT/ESGCJSGCT Joint Symposium

[JS-2] How to empower current gene and cell therapy approaches by next generation AAV vectors

^○Hildegard Büning (Hannover Medical School, Hannover, Germany)

Keywords:Dr. Büning has a long-standing expertise in the area of viral vector development and infection research. Key competences include cell entry (transductional), transcriptional and genomic targeting of Adeno-Associated Viral (AAV) vectors, vaccine development, and characterization of the AAV-host interaction including immune recognition.

1997-2003: Post-doctoral Fellow, Gene Center of the LMU Munich, Germany
2004-2015: Research Group Leader, Laboratory for AAV Vector Development, University of Cologne, Germany
Since 2015: Research Group Leader, Laboratory for Infection Biology & Gene Transfer, MHH, Germany
Since 2017: Deputy Director, Institute of Experimental Hematology, MHH, Germany